100 related articles for article (PubMed ID: 10661618)
1. The long-term tolerability and efficacy of OESCLIM: results of a 1-year study.
Taurelle R; L'Hermite M; Haenggi W; Lauritzen C; Studd JW
Maturitas; 1999 Nov; 33 Suppl 1():S73-81. PubMed ID: 10661618
[TBL] [Abstract][Full Text] [Related]
2. OESCLIM: pre-clinical and clinical profile.
Guy M
Maturitas; 1999 Nov; 33 Suppl 1():S49-55. PubMed ID: 10661615
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a low-dose of Oesclim (25 mcg daily) in the management of symptomatic menopausal women: a French open-label study.
Elia D; Tamborini A; Leocmach Y; Chadha-Boreham H
Curr Med Res Opin; 2000; 16(2):94-106. PubMed ID: 10893653
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of low-dose transdermal estrogen (Oesclim) in the treatment of menopausal symptoms.
Gadomska H; Barcz E; Cyganek A; Leocmach Y; Chadha-Boreham H; Marianowski L
Curr Med Res Opin; 2002; 18(2):97-102. PubMed ID: 12017217
[TBL] [Abstract][Full Text] [Related]
7. OESCLIM: summary of tolerability and safety.
Brackman F
Maturitas; 1999 Nov; 33 Suppl 1():S83-8. PubMed ID: 10661619
[TBL] [Abstract][Full Text] [Related]
8. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
9. OESCLIM: an advanced delivery system for HRT.
Munoz A
Maturitas; 1999 Nov; 33 Suppl 1():S39-47. PubMed ID: 10661614
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
von Holst T; Salbach B
Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
[TBL] [Abstract][Full Text] [Related]
11. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
Lübbert H; Nauert C
Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319
[TBL] [Abstract][Full Text] [Related]
12. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms.
Rozenberg S; Caubel P; Lim PC
Int J Gynaecol Obstet; 2001 Mar; 72(3):235-43. PubMed ID: 11226444
[TBL] [Abstract][Full Text] [Related]
13. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
[TBL] [Abstract][Full Text] [Related]
15. Aerodiol versus the transdermal route: perspectives for patient preference.
Lopes P; Rozenberg S; Graaf J; Fernandez-Villoria E; Marianowski L
Maturitas; 2001 Jun; 38 Suppl 1():S31-9. PubMed ID: 11390122
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
de Vrijer B; Snijders MP; Troostwijk AL; Thé S; Iding RJ; Friese S; Smit DA; Schierbeek JM; Brandts H; van Kempen PJ; van Buuren I; Monza G
Maturitas; 2000 Jan; 34(1):47-55. PubMed ID: 10687882
[TBL] [Abstract][Full Text] [Related]
17. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group.
al-Azzawi F; Van der Mooren MJ; Rolland R; Hirvonen E
Br J Clin Pract; 1997; 51(1):20-3, 25-6. PubMed ID: 9158267
[TBL] [Abstract][Full Text] [Related]
18. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women.
Ylikorkala O; Rozenberg S
Maturitas; 2000 Dec; 37(2):83-93. PubMed ID: 11137327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]